A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patient with Platinum Resistant/Refractory Advanced Ovarian Cancers

Trial Profile

A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patient with Platinum Resistant/Refractory Advanced Ovarian Cancers

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Seribantumab (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2016 Results published in the Journal of Clinical Oncology
    • 18 May 2016 Results from this and 2 other trials were presented at the AACR Precision Medicine Series, according to a Merrimack Pharmaceuticals media release.
    • 30 Sep 2014 According to a Merrimack Pharmaceuticals media release, biomarker data was presented at the European Society of Medical Oncology (ESMO) 2014 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top